Novo Nordisk has acquired rights to a preclinical drug that could be used to treat non-alcoholic steatohepatitis (NASH), the fatty liver disease that could generate billions of dollars for
Therapeutic or focused ultrasound began being applied to neurologic conditions less than a decade ago, but its potential in a wide spectrum of brain applications is high.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.
